Credit Agricole’s Filana Therapeutics FLNA Stock Holding History

Credit Agricole’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400	Closed	-$11K	–	716
2022 Q2	$11K	Hold	400	–	–	﹤0.01%	603
2022 Q1	$15K	Hold	400	–	–	﹤0.01%	616
2021 Q4	$17K	Buy	+400	New	+$21K	﹤0.01%	612

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Agricole's FLNA Position: Q3 2022 in Review

Credit Agricole sold out of Filana Therapeutics (FLNA) in Q3 2022, closing a stake of 400 shares — an estimated $11K sold.

Credit Agricole first reported a position in FLNA in Q4 2021 and held it in 3 quarters. The position peaked at $17K in Q4 2021. 175 funds tracked by Wall St. Rank hold FLNA as of Q3 2022.

Credit Agricole reported no remaining Filana Therapeutics position as of Q3 2022 after selling out during the quarter.
Credit Agricole sold 400 Filana Therapeutics shares in Q3 2022, an estimated $11K.
Credit Agricole first reported a position in Filana Therapeutics in Q4 2021 and held it in 3 quarters.
Credit Agricole's Filana Therapeutics position peaked at $17K in Q4 2021.
175 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2022.

Based on Credit Agricole's 13F filing for Q3 2022, filed 10 Nov 2022.